Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
NeurogesX
December 14, 2016
Centrexion still has work to do after pain Triumph
July 04, 2013
Japan continues to dominate small cap risers but US biotech muscles in
April 08, 2013
Japan dominates small cap stock price rises in Q1
January 06, 2012
Small caps produce clear winners and losers in 2011
October 04, 2011
Pharmasset continues to lead small cap gainers so far in 2011
July 05, 2011
Pharmasset success story leads small caps in first half of 2011
June 03, 2011
Product sales in 2010: hits and misses
November 19, 2009
NeurogesX achieves pain free approval and heads for US market
August 11, 2009
Astellas set back highlights need for pipeline expansion
August 06, 2009
FDA PDUFA date decision takes the heat out of NeurogesX shares.
June 19, 2009
Companies still desperate for a partner
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
Editor's Picks
June 07, 2021
Biogen makes history with Alzheimer’s approval
June 08, 2021
Biogen and the social contract
June 09, 2021
Asco 2021 story roundup
June 03, 2021
Asco 2021 justifies Novartis’s radioligand Vision
May 26, 2021
Roche remains big pharma’s biggest R&D spender
